US LNG exports surge but will buyers in China turn up?
Enfusion , Inc. (NYSE:ENFN), a $1.46 billion market cap company, recently saw a notable stock sale by its Chief Executive Officer, Oleg Movchan. According to a regulatory filing, Movchan sold 11,452 shares of Class A common stock on March 6, 2025, at an average price of $11.393 per share, totaling approximately $130,472. The transaction comes as ENFN trades near its 52-week high of $11.80, having gained nearly 40% over the past six months.
The sale was executed to cover tax withholding obligations related to the issuance of shares and was not a discretionary trade by Movchan. Post-transaction, Movchan, through CSL (OTC:CSLLY) Tech Holdings LLC, holds 631,847 shares of Enfusion. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 3.42 and operates with moderate debt levels, while showing healthy revenue growth of 15.5% in the last twelve months.
Movchan is the manager of CSL Tech Holdings LLC and has dispositive voting power over the shares held by the entity. However, he disclaims beneficial ownership except to the extent of his pecuniary interest.
This transaction highlights the ongoing management of stock holdings by executives, a common practice in corporate governance to meet tax obligations.
In other recent news, Enfusion Inc has been the subject of significant developments following its fourth-quarter earnings announcement and acquisition agreement with Clearwater Analytics. The company reported its latest financial performance this week, though specific implications on its stock valuation were not detailed by analysts. The acquisition agreement, priced at $11.25 per share, has influenced several analyst ratings and price targets. Stifel downgraded Enfusion from Buy to Hold, aligning its price target with the acquisition price, which they consider a fair valuation. Morgan Stanley (NYSE:MS) also downgraded the stock from Overweight to Equal-weight, citing the acquisition as a catalyst for the change, despite raising the price target to match the $11.25 offer. Analysts from both firms suggest that the acquisition provides a clear value realization for shareholders. They also note that the deal addresses previous concerns about Enfusion’s market position and growth prospects. With these developments, investors are closely monitoring the situation as the acquisition progresses.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.